Else Nutrn (OTCMKTS:BABYF – Get Free Report) and AtriCure (NASDAQ:ATRC – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Volatility & Risk
Else Nutrn has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.
Earnings and Valuation
This table compares Else Nutrn and AtriCure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Else Nutrn | $5.82 million | 5.14 | -$11.08 million | ($0.11) | -0.73 |
| AtriCure | $518.31 million | 3.17 | -$44.70 million | ($0.61) | -54.20 |
Else Nutrn has higher earnings, but lower revenue than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Else Nutrn, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
99.1% of AtriCure shares are owned by institutional investors. 3.5% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Else Nutrn and AtriCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Else Nutrn | -180.47% | -843.88% | -168.42% |
| AtriCure | -5.55% | -2.56% | -1.95% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Else Nutrn and AtriCure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Else Nutrn | 0 | 0 | 0 | 0 | 0.00 |
| AtriCure | 1 | 0 | 10 | 0 | 2.82 |
AtriCure has a consensus target price of $52.22, indicating a potential upside of 57.96%. Given AtriCure’s stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than Else Nutrn.
Summary
AtriCure beats Else Nutrn on 10 of the 14 factors compared between the two stocks.
About Else Nutrn
Else Nutrition Holdings Inc. focuses on the research, development, manufacturing, marketing, and sale of plant-based food and nutrition products for infants, toddlers, children's, and adults in North America, Israel, Australia, and New Zealand. It offers baby and toddler snacks; baby feeding accessories, such as feeding bottles and teats; plant-based baby and toddler nutrition formula products; kids and adult nutrition products; and complementary food products for babies, as well as toddler drink for toddlers ages 12-36 months; and follow-on formula for infants. The company provides its products through online. Else Nutrition Holdings Inc. was founded in 2012 and is headquartered in Tel Aviv, Israel.
About AtriCure
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Receive News & Ratings for Else Nutrn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Else Nutrn and related companies with MarketBeat.com's FREE daily email newsletter.
